<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769417</url>
  </required_header>
  <id_info>
    <org_study_id>CD-ID-MEDI4893-1133</org_study_id>
    <nct_id>NCT01769417</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first time in human study enrolling approximately 33 healthy adult&#xD;
      subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the&#xD;
      safety, tolerability and PK of MEDI4893 in healthy adult volunteers administered as a single&#xD;
      IV dose compared with placebo, across 4 cohorts. The 4 dose cohorts will enroll sequentially.&#xD;
      Subjects will be followed for safety from the time of Informed Consent through 360 days post&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to&#xD;
      evaluate the safety, tolerability and pharmacokinetics of MEDI4893, an extended half-life&#xD;
      human monoclonal antibody against Staphylococcus aureus alpha toxin, in healthy adult&#xD;
      subjects. Approximately 33 subjects will be enrolled across 4 fixed dose cohorts at 1 study&#xD;
      site . This study will last approximately 389 days, constituting a screening period of up to&#xD;
      28 days, 1 day of investigational product administration, and a 360 day safety follow up&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurence of adverse events and serious adverse events.</measure>
    <time_frame>From the time of informed consent through 360 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Sign Measurements</measure>
    <time_frame>Pre-dose through Study Day 15</time_frame>
    <description>blood pressure, heart rate, respiratory rate, temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Safety lab measurements</measure>
    <time_frame>from Day 1 (pre-dose) through 90 days post dose</time_frame>
    <description>Chemistry, Hematology and urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessments - Serum</measure>
    <time_frame>Pre-dose through 360 days post dose</time_frame>
    <description>MEDI4893 Pharmacokinetic parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti Drug Antibody (ADA) Assessments - Serum</measure>
    <time_frame>Pre-dose through 360 days post dose</time_frame>
    <description>ADA responses to MEDI4893.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4893</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4893</intervention_name>
    <description>Human immunoglobulin G1 kappa monoclonal antibody</description>
    <arm_group_label>MEDI4893</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 through 65 years at screening.&#xD;
&#xD;
          2. Written informed consent and any locally required authorization (eg, HIPAA) obtained&#xD;
             from the subject prior to performing any protocol-related procedures, including&#xD;
             screening evaluations.&#xD;
&#xD;
          3. Females of childbearing age using contraception for at least 28 days prior to&#xD;
             receiving the dose of investigational product, and for 1 year after receiving IP.&#xD;
&#xD;
          4. Weight ≥ 45 kg and ≤ 110 kg at screening.&#xD;
&#xD;
          5. Healthy by medical history and physical examination at screening.&#xD;
&#xD;
          6. Systolic blood pressure (BP) &lt; 140 mm Hg and diastolic BP &lt; 90 mm Hg at screening.&#xD;
&#xD;
          7. Normal electrocardiogram (ECG) at screening.&#xD;
&#xD;
          8. Able to complete the 360-day postdose follow-up period as required by the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of the investigational product or interpretation of subject safety or study&#xD;
             results.&#xD;
&#xD;
          2. Employees of the sponsor, clinical study site, or any other individuals involved with&#xD;
             the conduct of the study, or immediate family members of such individuals.&#xD;
&#xD;
          3. Acute illness at study entry.&#xD;
&#xD;
          4. Fever 99.5F or higher on day of dosing.&#xD;
&#xD;
          5. Any drug therapy within 7 days prior to Day 1.&#xD;
&#xD;
          6. Blood donation in excess of 400 mL within 6 months prior to study entry.&#xD;
&#xD;
          7. Receipt of immunoglobulin or blood products within 6 months prior to study entry.&#xD;
&#xD;
          8. Receipt of any prior investigational drug or investigational vaccine within 120 days&#xD;
             prior to investigational product dosing or planned dosing&#xD;
&#xD;
          9. Receipt of any standard vaccine within 14 days prior to investigational product&#xD;
             dosing.&#xD;
&#xD;
         10. Previous receipt of a monoclonal antibody.&#xD;
&#xD;
         11. Receipt of immunosuppressive medications in the prior year or any active or prior&#xD;
             history of immunodeficiency. Any course of systemic corticosteroids of more than 7 day&#xD;
             duration during the prior year excludes a subject.&#xD;
&#xD;
         12. History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the investigational product.&#xD;
&#xD;
         13. Previous medical history or evidence of an intercurrent illness that may compromise&#xD;
             the safety of the subject in the study.&#xD;
&#xD;
         14. Evidence of any systemic disease on physical examination at screening.&#xD;
&#xD;
         15. Evidence of infection (ie, positive laboratory test result) with hepatitis A, B, or C&#xD;
             virus or human immunodeficiency virus (HIV) at screening.&#xD;
&#xD;
         16. Any of the following at screening:&#xD;
&#xD;
               1. Hemoglobin &lt; 12.0 g/dL for males and &lt; 11.5 g/dL for females.&#xD;
&#xD;
               2. WBC count &lt; 3,800/mm3.&#xD;
&#xD;
               3. Platelet count &lt; 140,000/mm3.&#xD;
&#xD;
               4. AST, ALT, BUN, serum creatinine &gt; upper limit of normal (ULN).&#xD;
&#xD;
               5. Positive Urine Class A drug screen.&#xD;
&#xD;
               6. Other abnormal laboratory values in the screening panel, which in the opinion of&#xD;
                  the principal investigator, are judged to be clinically significant or&#xD;
                  potentially confound study results.&#xD;
&#xD;
         17. Pregnant or nursing mother.&#xD;
&#xD;
         18. Active alcohol or drug abuse or history of alcohol or drug abuse that, in the opinion&#xD;
             of the principal investigator, might compromise subject safety, study safety&#xD;
             assessments, or ability of subject to comply with study requirements.&#xD;
&#xD;
         19. Concurrent enrollment in another interventional study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Schwartz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan Jafri, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

